Artivion, Inc. · NYSE (us_market)
Healthcare · Medical Devices · United States
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-23$47.18 RISE2026-04-06$33.45 PEAK2026-04-20$38.80 118d | -29.1% 104d | Missed | Missed | — | — | +16.0% 14d | Missed |
DROP2025-02-05$31.70 RISE2025-04-08$22.19 PEAK2025-06-27$31.19 142d | -30.0% 62d | Missed | Missed | — | — | +40.6% 80d | Missed |
DROP2023-08-30$17.52 RISE2023-10-27$12.33 PEAK2023-12-14$18.83 106d | -29.6% 58d | Missed | Missed | — | — | +52.7% 48d | Missed |
DROP2023-02-02$14.12 RISE2023-03-10$11.74 PEAK2023-06-06$15.45 124d | -16.9% 36d | Missed | Missed | — | — | +31.6% 88d | Missed |
DROP2022-08-25$22.89 RISE2022-12-28$11.56 PEAK2023-02-02$14.12 161d | -49.5% 125d | Missed | Missed | — | — | +22.1% 36d | Missed |
DROP2022-08-15$23.25 RISE2022-10-24$10.01 PEAK2022-12-13$13.62 120d | -56.9% 70d | Missed | Missed | — | — | +36.1% 50d | Missed |
DROP2022-04-25$22.91 RISE2022-06-14$16.26 PEAK2022-08-15$23.25 112d | -29.0% 50d | Missed | Missed | — | — | +43.0% 62d | Missed |
DROP2022-04-25$22.91 RISE2022-05-12$15.73 PEAK2022-08-08$21.95 105d | -31.3% 17d | Missed | Missed | — | — | +39.5% 88d | Missed |
DROP2021-09-27$23.40 RISE2022-02-03$16.95 PEAK2022-04-25$22.91 210d | -27.6% 129d | Missed | Missed | — | — | +35.2% 81d | Missed |
DROP2021-07-29$27.41 RISE2021-11-30$17.19 PEAK2022-01-03$21.72 158d | -37.3% 124d | Missed | Missed | — | — | +26.4% 34d | Missed |
DROP2021-02-24$26.31 RISE2021-03-24$22.07 PEAK2021-05-06$32.07 71d | -16.1% 28d | Missed | Missed | — | — | +45.3% 43d | Missed |
DROP2020-08-10$21.40 RISE2020-10-30$16.76 PEAK2021-01-21$25.30 164d | -21.7% 81d | Missed | Missed | — | — | +51.0% 83d | Missed |
DROP2020-06-05$25.24 RISE2020-09-14$16.35 PEAK2020-12-07$22.49 185d | -35.2% 101d | Missed | Missed | — | — | +37.6% 84d | Missed |
DROP2020-02-11$30.57 RISE2020-06-18$17.38 PEAK2020-08-10$21.40 181d | -43.1% 128d | Missed | Missed | — | — | +23.1% 53d | Missed |
DROP2020-02-11$30.57 RISE2020-03-23$14.66 PEAK2020-06-05$25.24 115d | -52.0% 41d | Missed | Missed | — | — | +72.2% 74d | Missed |
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 1.2% return has trailed the S&P 500 by 8.6 percentage points.
Last week's profit announcement from Artivion, Inc. ( NYSE:AORT ) was underwhelming for investors, despite headline...
Last week's profit announcement from Artivion, Inc. ( NYSE:AORT ) was underwhelming for investors, despite headline...
Artivion (NYSE:AORT) has completed its acquisition of Endospan following FDA approval of the NEXUS Aortic Arch System. The deal makes Artivion the only company offering a full suite of aortic arch solutions for complex aortic surgery. This positions Artivion to broaden its presence in both the U.S. and international markets for aortic procedures. Artivion, trading at $23.76, is coming into this news after a period of mixed share performance, with the stock down 37.0% over the past 30 days...
Artivion (NYSE:AORT) has completed its acquisition of Endospan following FDA approval of the NEXUS Aortic Arch System. The deal makes Artivion the only company offering a full suite of aortic arch solutions for complex aortic surgery. This positions Artivion to broaden its presence in both the U.S. and international markets for aortic procedures. Artivion, trading at $23.76, is coming into this news after a period of mixed share performance, with the stock down 37.0% over the past 30 days...
Artivion is targeting a $150 million annual U.S. market for the Nexus Aortic Arch System.
Artivion is targeting a $150 million annual U.S. market for the Nexus Aortic Arch System.
As per a 2019 deal, Artivion secured the rights to purchase Endospan upon the latter’s US approval of Nexus, a treatment for aortic arch syndrome.
As per a 2019 deal, Artivion secured the rights to purchase Endospan upon the latter’s US approval of Nexus, a treatment for aortic arch syndrome.
HERZLIYA, Israel, May 18, 2026--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for ope
Artivion Completes Acquisition of Endospan Ltd.
Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices.
Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices.
Artivion’s first quarter results for 2026 were met with a significant negative market reaction, with investors responding to shortfalls in adjusted profitability and a guidance revision for the year. Management attributed these results to lower-than-expected stent graft sales, particularly in international markets and the U.S., as well as delays in AMDS starter set sales due to hospital procurement hurdles. CEO Pat Mackin acknowledged, “There were two things that did not go as planned in the fir
Artivion’s first quarter results for 2026 were met with a significant negative market reaction, with investors responding to shortfalls in adjusted profitability and a guidance revision for the year. Management attributed these results to lower-than-expected stent graft sales, particularly in international markets and the U.S., as well as delays in AMDS starter set sales due to hospital procurement hurdles. CEO Pat Mackin acknowledged, “There were two things that did not go as planned in the fir
More than 1,500 stocks have reported earnings since the current season began, and the average stock that's reported has seen an average absolute one-day share price reaction of roughly 7%.
The "Affordable Growth" screen targets stocks with strong earnings momentum and reasonable valuations. Artivion Inc (NYSE:AORT) passes with high growth ratings, acceptable valuation, and solid financial health, making it a potential GARP candidate.
2026-05-12. The following slide deck was published by Artivion, Inc.
Shares of medical device company Artivion (NYSE:AORT) fell 26.8% in the afternoon session after it reported first-quarter results that missed Wall Street's profit expectations and lowered its full-year guidance for 2026.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AORT | -38.72% | -42.44% | -51.35% | -24.98% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -41.69% | -36.72% | -47.91% | -37.67% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 2.58M | $94.61M | 0.00% | Added+1.6% | 2026-03-31 |
| StateStreet | passive | 1.68M | $61.60M | 0.00% | Added+6.1% | 2026-03-31 |
| Wellington | fundamental | 1.16M | $42.36M | 0.01% | Trimmed-17.7% | 2026-03-31 |
| TwoSigma | quant | 725.9K | $26.58M | 0.02% | Added+63.7% | 2026-03-31 |
| DEShaw | quant | 6.5K | $238.98K | 0.00% | Added+26.6% | 2026-03-31 |
| TRowePrice | fundamental | 52.3K | $1.92K | 0.00% | Added+20.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | 0.11 | — | — |
| 2026-05-07 | 0.12 | 0.08 | -35.13% |
| 2026-02-12 | 0.18 | 0.17 | -3.41% |
| 2025-11-06 | 0.15 | 0.16 | +5.26% |
| 2025-08-07 | 0.13 | 0.24 | +92.00% |
| 2025-05-05 | 0.05 | 0.06 | +33.33% |
| 2025-02-24 | 0.04 | — | -100.00% |
| 2024-11-07 | 0.01 | 0.12 | +1100.00% |
| 2024-08-08 | 0.03 | 0.07 | +162.47% |
| 2024-05-06 | 0.02 | 0.06 | +157.18% |
| 2024-02-15 | — | 0.11 | — |
| 2023-11-02 | 0.03 | 0.02 | -33.33% |
| 2023-08-03 | 0.02 | 0.06 | +200.00% |
| 2023-05-04 | -0.02 | 0.02 | +188.89% |
| 2023-02-16 | -0.02 | 0.10 | +671.43% |
| 2022-11-03 | -0.04 | -0.05 | -11.11% |